Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Comparison Tests01:13

Multiple Comparison Tests

Multiple comparison test, abbreviated as MCT, is a post hoc analysis generally performed after comparing multiple samples with one or more tests. An MCT will help identify a significantly different sample among multiple samples or a factor among multiple factors.
It would be easy to compare two samples using a significance alpha level of 0.05. In other words, there is only one sample pair to be compared. However, it would be difficult to identify a significantly different sample if the number...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improving prediction of fetal/neonatal intracranial hemorrhage in HPA-1a alloimmunized pregnancies to guide antenatal management: An observational cohort study.

Acta obstetricia et gynecologica Scandinavica·2025
Same author

Corrigendum to "Platelet alloimmunization is associated with low grade chronic histiocytic intervillositis - A new link to a rare placental lesion?" [Placenta 112 (2021) 89-96].

Placenta·2025
Same author

Placenta-associated biomarkers and pregnancy outcome in HPA-1a alloimmunization: A prospective cohort study.

Placenta·2024
Same author

A Phase 1b PK/PD Study to Demonstrate Antigen Elimination with RLYB212, A Monoclonal Anti-HPA-1a Antibody for FNAIT Prevention.

Thrombosis and haemostasis·2024
Same author

What's with the boys? Lower birth weight in boys from HPA-1a alloimmunized pregnancies - New insights from a large prospective screening study in Poland.

Journal of reproductive immunology·2023
Same author

An HPA-1a-positive platelet-depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: a randomized, single-blind, placebo-controlled, single-center, phase 1/2 proof-of-concept study.

Journal of thrombosis and haemostasis : JTH·2023

Related Experiment Video

Updated: Jun 10, 2026

Quantifying X-Ray Fluorescence Data Using MAPS
14:58

Quantifying X-Ray Fluorescence Data Using MAPS

Published on: February 17, 2018

Quantitative MAIPA: Comparison of different MAIPA protocols.

Mette Kjær Killie1, Wahida Salma, Eirin Bertelsen

  • 1Department of Immunology and Transfusion Medicine, University Hospital of North Norway, 9038 Tromsø, Norway. mette.kjaer.killie@unn.no

Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis
|August 3, 2010
PubMed
Summary

Maternal anti-HPA 1a antibody levels predict severe neonatal alloimmune thrombocytopenia (NAIT). Optimizing the MAIPA assay is crucial for accurate quantitation and reliable clinical impact.

More Related Videos

Probe-based Real-time PCR Approaches for Quantitative Measurement of microRNAs
10:28

Probe-based Real-time PCR Approaches for Quantitative Measurement of microRNAs

Published on: April 14, 2015

Related Experiment Videos

Last Updated: Jun 10, 2026

Quantifying X-Ray Fluorescence Data Using MAPS
14:58

Quantifying X-Ray Fluorescence Data Using MAPS

Published on: February 17, 2018

Probe-based Real-time PCR Approaches for Quantitative Measurement of microRNAs
10:28

Probe-based Real-time PCR Approaches for Quantitative Measurement of microRNAs

Published on: April 14, 2015

Area of Science:

  • Immunology
  • Neonatal Medicine
  • Clinical Chemistry

Background:

  • Maternal anti-human platelet antigen 1a (HPA-1a) antibody levels are prognostic for neonatal alloimmune thrombocytopenia (NAIT).
  • Accurate quantitation of these antibodies is essential for identifying newborns at risk of severe NAIT.

Purpose of the Study:

  • To determine the optimal MAIPA (M-A-I-P-A) protocol for quantifying anti-HPA-1a antibodies.
  • To improve the reliability of NAIT risk assessment in newborns.

Main Methods:

  • Analysis of plasma for anti-HPA-1a antibodies using various monoclonal antibodies.
  • Comparison of results using lyophilized versus fresh platelets.
  • Evaluation of different MAIPA (M-A-I-P-A) assay protocols.

Main Results:

  • Significant variation in anti-HPA-1a antibody levels was observed with different monoclonal antibodies.
  • A strong correlation was found between maternal anti-HPA-1a antibody levels and neonatal platelet counts.
  • Assay sensitivity was dependent on the specific MAIPA (M-A-I-P-A) protocol employed.

Conclusions:

  • Consistent and reliable test results are critical for the clinical utility of anti-HPA-1a antibody testing.
  • Standardization of the MAIPA (M-A-I-P-A) assay is necessary for accurate NAIT risk stratification.